Esters for treatment of ocular inflammatory conditions

US10383839B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10383839-B2
Application numberUS-201213495049-A
CountryUS
Kind codeB2
Filing dateJun 13, 2012
Priority dateJun 30, 2011
Publication dateAug 20, 2019
Grant dateAug 20, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.

First claim

Opening claim text (preview).

What is claimed is: 1. An ophthalmic device for the treatment of ocular conditions comprising: a silicone hydrogel contact lens incorporating an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediatory and a monohydric alcohol selected from the group consisting of eicosapentaenoic acid ethyl ester and alpha-linolenic acid ethyl ester and mixtures thereof; wherein the ophthalmic device is contained in a sealed package in which the silicone hydrogel contact lens incorporating the ester of the anti-inflammatory lipid mediator is stored in the presence of a packing solution. 2. The ophthalmic device of claim 1 , wherein the ester or amide is present in the silicone hydrogel contact lens in a therapeutically effective amount. 3. The ophthalmic device of claim 1 , wherein the ester is present in the silicone hydrogel contact lens in an amount in the range of about 0.01% to 0.5% by weight. 4. The ophthalmic device of claim 1 , wherein the packing solution is water-based. 5. The ophthalmic device of claim 4 , wherein the packing solution further comprises one or more of the following: a surfactant, a wetting agent, a chelant, and an antioxidant. 6. The ophthalmic device of claim 5 , wherein the packing solution further comprises one or more ingredients selected from the group consisting of Tyloxapol™, methyl gluceth-20, Vitamin E, diethylenetriaminepentaacetic acid, boric acid, sodium borate, and sodium chloride. 7. The ophthalmic device of claim 1 , wherein upon wearing of the silicone hydrogel contact lens on-eye, the ester releases over time. 8. The ophthalmic device of claim 7 comprising a release rate of approximately 3 micrograms per hour after a first hour of wearing. 9. The ophthalmic device of claim 1 , wherein the ester is incorporated into the silicone hydrogel contact lens in an amount in the range of about 50 to about 620 micrograms per lens. 10. The ophthalmic device of claim 1 , wherein the silicone hydrogel contact lens is selected from the group consisting of balafilcon, acquafilcon, lotrafilcon, comfilcon, galyfilcon, senofilcon narafilcon, falcon II 3, or asmofilcon A. 11. The ophthalmic device of claim 1 wherein the ester is eicosapentaenoic acid ethyl ester. 12. The ophthalmic device of claim 1 wherein the ester is alpha-linolenic acid ethyl ester.

Assignees

Inventors

Classifications

  • Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

  • Artificial tears; Irrigation solutions · CPC title

  • Ophthalmic agents · CPC title

  • Drugs for disorders of the senses · CPC title

  • Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10383839B2 cover?
The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohy…
Who is the assignee on this patent?
Gallois Bernos Annabelle, Molock Jr Frank F, Davis Carrie L, and 5 more
What technology area does this patent fall under?
Primary CPC classification A61K31/232. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).